HER2+ Breast Cancer | Specialty

Case Study: HER2-Positive Oligometastatic Breast Cancer

January 22nd 2014

Phase III Clinical Trials in HER2-Positive Breast Cancer

January 22nd 2014

Novel Drug Development in Breast Cancer

January 22nd 2014

Role of Lapatinib in HER2-Positive Breast Cancer

January 22nd 2014

Recommendations for Optimal HER2 Testing in Breast Cancer

January 22nd 2014

T-DM1 in HER2-Positive Metastatic Breast Cancer

January 22nd 2014

PIK3CA Mutations in HER2-Positive Breast Cancer

January 22nd 2014

Frontline Pertuzumab for Metastatic Breast Cancer

January 22nd 2014

Treating Low-Risk HER2-Positive Breast Cancer

January 22nd 2014

Overview of HER2-Targeted Therapies in Breast Cancer

January 22nd 2014

Gradishar Provides Insight into New Breast Cancer Treatments

January 21st 2014

New treatments for HER2-positive (HER2+) tumors have dominated media coverage of breast cancer breakthroughs over the past year, but William Gradishar sees promise on many fronts.

BOLERO-3 Safety Analysis Finds Everolimus Regimen Is Manageable

December 13th 2013

The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable.

NeoALTTO Analysis Finds Significant Link Between pCR and Survival

December 12th 2013

Pathologic complete response to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.

No Benefit Found in Adding Bevacizumab to Adjuvant Therapy in HER2-Positive Breast Cancer

December 12th 2013

Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.

High Levels of Infiltrating Lymphocytes May Identify Better Response to Trastuzumab

December 12th 2013

New evidence suggests that HER2-positive breast cancer may not only be immunogenic, but also that trastuzumab may relieve suppression of antitumor immunity.

Dr. Loi on the Association Between TILs and Trastuzumab

December 11th 2013

Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.

New ASCO/CAP Guideline Enhances HER2 Testing in Breast Cancer

October 7th 2013

The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have released updated recommendations for HER2 testing in breast cancer.

Dual HER2 Blockade Less Effective in PI3KCA-Mutant Breast Cancer

October 1st 2013

Breast cancer patients with PI3KCA mutations are less likely to achieve a pathological complete response from dual HER2 blockade in the neoadjuvant setting.

BOLERO-3 Biomarker Study Provides Clues for Response to Everolimus

September 30th 2013

Exploratory analysis of biomarkers in the BOLERO-3 trial suggests that the addition of everolimus to trastuzumab plus vinorelbine for HER2-positive advanced breast cancer may be most beneficial in patients with low PTEN or high pS6 levels.

In Historic Vote, ODAC Suggests Approval of Neoadjuvant Pertuzumab Regimen

September 12th 2013

The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.